Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT04959201
PHASE2

Combination of NMDA-enhancing and Antioxidant Treatments for Schizophrenia

Sponsor: China Medical University Hospital

View on ClinicalTrials.gov

Summary

Previous studies found that some NMDA-enhancing agents were able to improve clinical symptoms of patients with schizophrenia. In addition, several drugs with antioxidant properties have been tested in clinical trials for the treatment of schizophrenia too. Whether combined treatment of an NMDA-enhancing agent and a drug with antioxidant property can be better than an NMDA-enhancing agent alone deserves study.

Key Details

Gender

All

Age Range

18 Years - 65 Years

Study Type

INTERVENTIONAL

Enrollment

90

Start Date

2020-11-30

Completion Date

2027-03

Last Updated

2025-02-19

Healthy Volunteers

No

Conditions

Interventions

DRUG

NMDAE plus AO

Use of an NMDA enhancer plus a drug with antioxidant property for the treatment of schizophrenia.

DRUG

NMDAE plus Placebo Cap

Use of an NMDA enhancer plus placebo as a comparator.

Locations (1)

Department of Psychiatry, China Medical University Hospital

Taichung, Taiwan